Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients with Pre-Existing Invasive Fungal Disease Undergoing Allogeneic Haematopoietic Stem Cell Transplantation — 5 Years Single Centre Experience

Varun Mehra, MRCP, FRCPath, Eleanor Barnwell, Ute Boczek, Stefanie Widya, Kavita Raj, MD PhD, Hugues De Lavallade, Donal McLornan, Victoria Potter, Carmel Rice, FRACP, FRCPA, MBBS, Christina Lim, Michelle Kenyon, Alessandra Bisquera, Judith Marsh, MD, M. Mansour Ceesay, MDFRCP,FRCPath, Antonio Pagliuca, MD, Ghulam Mufti, DM, FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 3216.

https://doi.org/10.1182/blood.V130.Suppl_1.3216.3216

Published: 2017

Journal Articles

EBV Reactivation Incidence and Severity in Multiple Sclerosis Patients Treated with Autologous Haematopoietic Stem Cell Transplant and Comparing with Aplastic Anaemia Treated with ATG—Single Site Experience

Blood (2017) 130 (Supplement 1): 4535.

https://doi.org/10.1182/blood.V130.Suppl_1.4535.4535

Published: 2017

Journal Articles

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19 + Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Blood (2017) 130 (Supplement 1): 887.

https://doi.org/10.1182/blood.V130.Suppl_1.887.887

Published: 2017

Journal Articles

Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance

Varun Mehra, MRCP, FRCPath, Titilola Oyebamiji, Stefanie Widya, Robin M. Ireland, FRCP, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Kavita Raj, MD PhD, Donal McLornan, Judith Marsh, MD, Victoria Potter, Joanna Large, Isabel Duggins, Aytug Kizilors, PhD, Nicholas Lea, PhD, Antonio Pagliuca, MD, Ghulam Mufti, DM, FRCP, FRCPath, Hugues De Lavallade

Blood (2017) 130 (Supplement 1): 5250.

https://doi.org/10.1182/blood.V130.Suppl_1.5250.5250

Published: 2017

Journal Articles

Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Meng Wang, MD PhD, Wenjia Wang, PhD, Ayesha Abeywardane, MD, Malinthi Adikarama, MD, Donal McLornan, MD PhD FRCPath, Kavita Raj, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Stephen Devereux, MD PhD FRCPath, Ghulam J. Mufti, DM, FRCP, FRCPath, Antonio Pagliuca, MD FRCP, FRCPath, Victoria T Potter, MD FRCPA, FRACP, Aleksandar Mijovic

Blood (2014) 124 (21): 2512.

https://doi.org/10.1182/blood.V124.21.2512.2512

Published: 2014

Journal Articles

Patient/Donor CMV Matching Is a Critical Determinant of Survival in Unrelated Donor Haematopoietic Stem Cell Transplantation

Bronwen E. Shaw, PhD MRCP, FRCPath, Neema P Mayor, Szydlo Richard, Will P Bultitude, Kirkland Keiren, Perry Julia, Wilson Marie, Andrew Clark, Stephen Mackinnon, David I Marks, Antonio Pagliuca, MD FRCP, FRCPath, Michael Potter, PhD, Nigel Russell, Kirsty Thomson, J. Alejandro Madrigal, MD PhD, Steven GE Marsh, PhD

Blood (2014) 124 (21): 1207.

https://doi.org/10.1182/blood.V124.21.1207.1207

Published: 2014

Journal Articles

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients

Selim Corbacioglu, MD, Enric Carreras, MD PhD, Mohamad Mohty, MD PhD, Antonio Pagliuca, MD FRCP, FRCPath, Maria Ballabio, MD, Robin L. Hume, MS, Valeria Bandiera, Giorgia Finetto, Paul G. Richardson

Blood (2014) 124 (21): 1138.

https://doi.org/10.1182/blood.V124.21.1138.1138

Published: 2014

Journal Articles

Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity

Anita Sarma, MBChB, BSc, MRCP, Victoria T Potter, MD FRCPA, FRACP, Jennifer Clay, BM BS, FRACP, FRCPA, Donal McLornan, MD PhD FRCPath, Hugues de Lavallade, MD PhD, Kavita Raj, Judith C. W. Marsh, Austin Kulasekararaj, Antonio Pagliuca, MD FRCP, FRCPath, Ghulam Mufti, MD DM, FRCP, FRCPath

Blood (2014) 124 (21): 1236.

https://doi.org/10.1182/blood.V124.21.1236.1236

Published: 2014

Journal Articles

Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).

Karthik Ramasamy, MD, Shameem Mahmood, MD, Laurence Pearce, MD, ZiYi Lim, MD, Dariusz Ladon, PhD, Antonio Pagliuca, MD, Stephen Devereux, MD, PhD, Ghulam J. Mufti, MD, DM, Stephen Schey, MD

Blood (2007) 110 (11): 3034.

https://doi.org/10.1182/blood.V110.11.3034.3034

Published: 2007

Journal Articles

Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Wendy Ingram, MD, Zi Y. Lim, MD, Michelle Kenyon, RN, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Y.L. Ho, MD, Mufti Ghulam, MD

Blood (2006) 108 (11): 3108.

https://doi.org/10.1182/blood.V108.11.3108.3108

Published: 2006

Journal Articles

Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report.

Frederick E. Chen, MD, Humayun N. Ahmad, MD, Pritesh Junagade, MD, Zi Lim, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Ho, MD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 5406.

https://doi.org/10.1182/blood.V106.11.5406.5406

Published: 2005

Journal Articles

Reduced Intensity Allogeneic Transplantation Using BEAM-Alemtuzumab in Patients with Lymphoid Malignancy: Long Term Results and Impact of Intervention with DLI.

Emma P. Das-Gupta, DM, Jennifer L. Byrne, PhD, Charles Craddock, MD, Stephen Robinson, PhD, Stephen Devereux, MD, Antonio Pagliuca, MD, Grant McQuaker, DM, Andrew P. Haynes, DM, Ghulam Mufti, MD, Nigel H. Russell, MD

Blood (2005) 106 (11): 2890.

https://doi.org/10.1182/blood.V106.11.2890.2890

Published: 2005

Journal Articles

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.

Raj K. Patel, MD, Nicholas Lea, PhD, Michael A. Heneghan, MD, Nigel Westwood, PhD, Dragana Milojkovic, MD, Kumar Thanigaikumar, MD, Deborah Yallop, MD, Roopen Arya, PhD, Antonio Pagliuca, MD, Joop Gaken, PhD, Nigel A. Heaton, MD, Ghulam J. Mufti, MD

Blood (2005) 106 (11): 2588.

https://doi.org/10.1182/blood.V106.11.2588.2588

Published: 2005

Journal Articles

Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate.

Dragana Milojkovic, MD, Satyajit Sahu, MD, Jeffery Henderson, MD, Barbara H. Czepulkowski, John R. Salisbury, MD, William T. Bellamy, MD, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Y.L. Ho, MD, Ghulam J. Mufti, MD

Blood (2004) 104 (11): 1999.

https://doi.org/10.1182/blood.V104.11.1999.1999

Published: 2004

Journal Articles

Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT).

Aloysius Y.L. Ho, MD, Sujal R. Desai, MD, Ian D.P. Stanton, MD, Susan J. Copley, MD, Athol U. Wells, MD, Antonio Pagliuca, MD, Stephen Devereux, MD, Ghulam J. Mufti, MD

Blood (2004) 104 (11): 1831.

https://doi.org/10.1182/blood.V104.11.1831.1831

Published: 2004

Journal Articles

Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT).

Kavita Raj, MD, Maadh Aldouri, MD, Aloysius Ho, MD, Antonio Pagliuca, MD, Stephen Devereux, MD, Ghulam Mufti, MD

Blood (2004) 104 (11): 1806.

https://doi.org/10.1182/blood.V104.11.1806.1806

Published: 2004

NARROW

Outcomes of Patients with Pre-Existing Invasive Fungal Disease Undergoing Allogeneic Haematopoietic Stem Cell Transplantation — 5 Years Single Centre Experience

EBV Reactivation Incidence and Severity in Multiple Sclerosis Patients Treated with Autologous Haematopoietic Stem Cell Transplant and Comparing with Aplastic Anaemia Treated with ATG—Single Site Experience

Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19 + Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Low-Dose Second Generation TKI Is an Effective Approach to Reduce TKI Related Side Effects and Toxicity While Preserving Molecular Response in CML Patients with TKI Intolerance

Increased Mortality in Patients with Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Patient/Donor CMV Matching Is a Critical Determinant of Survival in Unrelated Donor Haematopoietic Stem Cell Transplantation

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: An Update from the International Compassionate Use Program in 710 Patients

Busulfan-Dose Escalation in Reduced Intensity Stem Cell Transplantation (RIC-HSCT) Results in Good Outcomes for Patients with MDS and AML without Increased Toxicity

Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).

Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report.

Reduced Intensity Allogeneic Transplantation Using BEAM-Alemtuzumab in Patients with Lymphoid Malignancy: Long Term Results and Impact of Intervention with DLI.

Prevalence of the Activating JAK2 Tyrosine Kinase Mutation V617F in the Budd-Chiari Syndrome.

Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate.

Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT).

Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only